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Abstract
Background: Our recent paper, based on a pilot cohort of 119 women, showed that serum progesterone
<35 nmol/L was prognostic of spontaneous miscarriage by 16 weeks in women with threatened miscarriage in
early pregnancy. Using a larger cohort of women from the same setting (validation cohort), we aim to assess the
validity of serum progesterone <35 nmol/L with the outcome of spontaneous miscarriage by 16 weeks.
Methods: In a prospective cohort study, 360 pregnant women presenting with threatened miscarriage between
gestation weeks 6–10 at a tertiary hospital emergency unit for women in Singapore were recruited for this study.
The main outcome measure measured is spontaneous miscarriage prior to week 16 of gestation. Area under the
ROC curve (AUC) and test characteristics (sensitivity, specificity, positive and negative predictive value) at a serum
progesterone cutpoint of <35 nmol/L for predicting high and low risk of spontaneous miscarriage by 16 weeks
were compared between the Pilot and Validation cohorts.
Results: Test characteristics and AUC values using serum progesterone <35 nmol/L in the validation cohort were
not significantly different from those in the Pilot cohort, demonstrating excellent accuracy and reproducibility of
the proposed serum progesterone cut-off level.
Conclusions: The cut-off value for serum progesterone (35 nmol/L) demonstrated clinical relevance and allow
clinicians to stratify patients into high and low risk groups for spontaneous miscarriage.
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Background
Threatened miscarriage—defined as an ongoing preg-
nancy associated with vaginal bleeding, with or without
abdominal pain [1]—is the most common gynecological
emergency, occurring in 15–20% of ongoing pregnancies
[2], with 25% progressing to spontaneous miscarriage [3,
4]. Many clinical resources are utilized in attempting a
definitive diagnosis of spontaneous miscarriage among
women with threatened miscarriage, as not all are at
equal risk of miscarriage. Individualizing outpatient
management based on an initial risk evaluation would
be a boon to clinical care and suggest any additional
therapy.
While maternal factors like older age (>33 years) and
lower body mass index (BMI) <20 kg/m2 have been
found to contribute to spontaneous miscarriage [5], re-
cent focus has been on identifying serum biological
markers prognostic of spontaneous miscarriage. A recent
meta-analysis by Pillai et al of prospective studies inves-
tigating biomarkers to determine pregnancy outcome for
women presenting with threatened miscarriage have
showed conflicting results with the need for larger stud-
ies and further validation [6]. Other studies have looked
at various biomarkers such as serum beta HCG,
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estradiol, PAPP-A, inhibin, CA 125 as well as progester-
one. In addition, other studies have also looked at using
different combination of maternal demographics, serum
biomarkers and ultrasound features to predict pregnancy
viability that shows promise but require the implementa-
tion of a mathematical model and algorithm. This could
prove to be unwieldy in a busy clinical service due to
multiple variables that need to be collected in order to
use the model effectively [7–10].
Presently, the most promising is serum progesterone.
A recent prospective cohort study of women with no
signs of threatened miscarriage from 4 to 12 weeks of
gestation reported risk of miscarriage to be significantly
higher among women with low serum progesterone
(<38.3 nmol/L or 12 ng/ml) [5]. Progesterone levels were
48% lower in women experiencing threatened miscar-
riage with subsequent spontaneous miscarriage com-
pared to women who delivered at term. [9, 11] In our
group’s paper, serum progesterone levels were signifi-
cantly lower in women presenting with threatened mis-
carriage who subsequently experienced spontaneous
miscarriage by 16 weeks gestation compared to those
who did not miscarry. A cut-off serum progesterone
level of 35 nmol/L was proposed to prognosticate low
and high risk for spontaneous miscarriage after present-
ing with threatened miscarriage in early pregnancy [12].
Notwithstanding these findings, serum progesterone is
currently not used for miscarriage risk assessment in a
clinical setting. One explanation may be insufficient evi-
dence regarding appropriate or ‘optimal’ serum proges-
terone cut-off levels for risk stratification of spontaneous
miscarriage. Thus, a validated serum progesterone cut-
off as a prognostic risk assessment will allow clinicians
the means to better stratify patients into low- and high-
risk populations.
The current study employed a large, prospective co-
hort (Validation cohort) with the aim of validating the
serum progesterone cut-off value of 35 nmol/L based on
the results of an earlier, smaller study at the same insti-
tution (Pilot cohort). We compared areas under ROC
curves (AUCs) as well as sensitivity, specificity, positive
and negative predictive values between the Pilot and Val-
idation cohorts using 35 nmol/L as the risk prognosis
cut-off for spontaneous miscarriage at or before 16 weeks
of gestation in women presenting with threatened mis-
carriage in weeks 6–10 of pregnancy.
Methods
A total of 360 pregnant women, aged 21 years and above,
presenting at the KK Women’s and Children’s Hospital
(KKH) 24-h Women’s Clinic from September 2013 to June
2015 were recruited in the Validation cohort. Inclusion cri-
teria were a single intrauterine pregnancy between gesta-
tion weeks 6 to 10 (confirmed and dated by
ultrasonography), with pregnancy-related per vagina
bleeding. Women with previous episodes of per va-
gina bleeding or those treated with progesterone for
previous per vagina bleeding in the current preg-
nancy, or women diagnosed with inevitable miscar-
riage, missed miscarriage, blighted ovum or planned
termination of pregnancy were excluded (Fig. 1).
Maternal blood samples were taken to measure serum
progesterone level at presentation. Blood was collected
in plain tubes and centrifuged for 10 min at 3000 g
within 2 h of collection. Serum progesterone level was
measured in the KKH clinical laboratory using a com-
mercial ARCHITECT progesterone kit (Abbott, Ireland).
Covariates for the analysis were maternal demograph-
ics, health, obstetric and lifestyle factors collected by an
investigator administered questionnaire in either English
or Chinese (Table 1).
Outcome measures and follow-up
The primary outcome measured was spontaneous mis-
carriage, defined by self-reported uterine evacuation
after inevitable or incomplete miscarriage, or complete
miscarriage with an empty uterus, by the 16th week of
gestation. All participants were contacted at the 16th
week of pregnancy to verify pregnancy status.
Statistical Methods
The progesterone cut-off of <35 nmol/L for high risk of
miscarriage before the 16th week of pregnancy was de-
termined and developed using the Pilot study cohort as
reported in Ku et al. [12] The <35 nmol/L serum proges-
terone cut-off form the basis for our validation study.
Baseline maternal demographics and pregnancy charac-
teristics were statistically compared between the Pilot and
the Validation cohorts with respect to two patient sub-
groups: (i) patients who experienced spontaneous miscar-
riage at 16 weeks of gestation and (ii) patients with
ongoing pregnancy at 16 weeks gestation. The 2-sample t-
test was used to compare continuous baseline variables
and Fisher’s exact test to compare categorical variables.
Logistic regression equations were fitted to the re-
spective Pilot and Validation cohort data sets. The out-
come was the binary response ‘Yes/No’ corresponding to
occurrence/non-occurrence of spontaneous miscarriage.
The single predictor was progesterone level (nmol/L).
Parameter estimates were obtained for the intercept (b0)
and progesterone coefficient (b1). ROC analysis was per-
formed using progesterone concentration as a continu-
ous variable. The Youden criterion, which consists of
identifying the value of progesterone that maximizes the
sum of sensitivity and specificity, was applied to identify
the ‘optimum’ progesterone cut-off for each cohort.
ROC curves and AUCs for the Pilot and Validation co-
horts were computed and compared statistically the
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using the approach of Hanley and McNeil for comparing
independent ROC curves derived from different samples.
95% confidence intervals on the difference between the
Pilot and Validation AUCs were obtained.
Using the progesterone cut-off of <35 nmol/L, test
parameters of sensitivity, specificity, PPV and NPV
were estimated and compared between the Pilot and
Validation cohorts using Fisher’s exact test. Exact
Clopper-Pearson 95% confidence intervals were calcu-
lated on test parameter estimates. Differences in Pilot
and Validation parameter estimates were obtained and
95% confidence intervals on differences were calcu-
lated using a normal approximation approach. Likeli-
hood ratios corresponding to positive (LR+) and
negative (LR-) test outcomes were calculated. Agree-
ment of actual versus predicted Validation cohort
miscarriages based on the <35 nmol/L cut-off was
assessed using McNemar’s test. Corresponding confi-
dence intervals on the difference were calculated
using the Wald z method for differences of correlated
proportions. Analyses were performed using SAS
software version 9.3 (SAS Institute Inc., Cary, North
Carolina, USA).
Results
Of the 360 women recruited in the Validation cohort, 11
were lost to follow up and 3 withdrew from the study due
to induced termination of pregnancy. Of the 346 women
included in the analysis, 70 (20.2%) experienced spontan-
eous miscarriage prior to week 16. Of the 119 women in
the Pilot cohort, 30 (25.2%) experienced spontaneous mis-
carriage prior to week 16 of gestation. The difference (95%
Confidence Interval (CI)) in incidence proportions be-
tween the Pilot and Validation cohorts was 0.05 (-0.03,
0.14) and not statistically significant (p = 0.301).
Serum progesterone levels (nmol/L) did not differ sig-
nificantly between Pilot (P) and Validation (V) cohorts
for women with ongoing pregnancies at 16 weeks (P-
59.8, V-60.3; p = 0.848) or women experiencing spontan-
eous miscarriage prior to week 16 (P-26.4, V-31.4; p =
0.237). In women with ongoing pregnancy at week 16,
the only maternal demographic and clinical variables
Fig. 1 Sample selection flow chart
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exhibiting a statistically significant difference between
the two cohorts were presence of fetal pole (%) (P-93.3,
V-100; p = 0.0002) and fetal heart (%) (P-87.6, V-95.6; p
= 0.011). The same held true in women with
spontaneous miscarriage prior to week 16, with signifi-
cant differences in presence of fetal pole (P-50.0, V-100;
p <0.0001) and fetal heart (P-30.0, V-70.0; p = 0.0003)
(Table 1).
Table 1 Comparison of serum progesterone levels and maternal characteristics at baseline by pregnancy status at 16 weeks
gestation for Pilot and Validation cohorts




Validation Cohort (N = 276) p value Pilot Cohort
(N = 30)
Validation Cohort (N = 70) p value
Serum biological markers
Progesterone, mean ± SD (nmol/L) 59.8 ± 23.5 60.3 ± 22.7 0.848 26.4 ± 17.1 31.4 ± 20.1 0.237
Demographics
Age, mean ± SD (years) 29.3 ± 4.83 30.3 ± 4.10 0.0769 31.3 ± 4.73 31.6 ± 5.22 0.774
Age of spouse, mean ± SD (years) 32.9 ± 5.43 33.1 ± 5.96 0.772 33.9 ± 5.10 34.6 ± 6.38 0.628
Race
Chinese (%) 53.9 52.0 0.271 53.3 38.6 0.396
Malay (%) 19.1 25.5 16.7 31.4
Indian (%) 16.9 10.2 16.7 14.3
Others (%) 10.1 12.4 13.3 15.7
Marital status
Married 92.1 94.6 0.444 90.0 97.1 0.158
Single 7.87 5.45 10.0 2.86
Highest educational level
University degree (%) 42.7 39.3 0.179 46.7 42.9 0.724
ITE or polytechnic (%) 30.3 40.4 36.7 32.9
Primary and secondary (%) 27.0 20.4 16.7 24.3
Health, obstetric and lifestyle factors
Planned Pregnancy (%) 59.6 58.2 0.902 63.3 44.3 0.126
Gestation age at recruitment, mean (wks) 7.49 ± 1.43 7.48 ± 1.47 0.968 6.89 ± 1.30 6.63 ± 1.06 0.311
Fetal pole present (%) 93.3 100 0.0002 50.0 100 <0.0001
Fetal heart present (%) 87.6 95.6 0.011 30.0 70.0 0.0003
Number of children
None (%) 55.1 45.5 0.143 43.3 32.9 0.367
1 or more (%) 44.9 54.6 56.7 67.1
Previous miscarriage (%) 20.2 24.0 0.563 20.0 22.9 1.000
BMI, mean ± SD (kg/m2) 23.7 ± 5.09 22.9 ± 4.29 0.204 22.1 ± 3.81 23.6 ± 4.81 0.0903
Medical comorbidities
Diabetes mellitus (%) 0 0.360 1.000 0 0 1.000
Hypertension (%) 0 0 1.000 0 0 1.000
Thyroid disease (%) 1.12 1.09 1.000 0 1.43 1.000
Gynecological disease (%) 12.4 12.0 1.000 0 10 0.0991
Smoking during pregnancy (%) 3.37 5.45 0.579 0 5.71 0.313
Exposed second hand smoke at home (%) 40.5 44.7 0.539 30 38.6 0.498
Alcohol during pregnancy (%) 1.12 0.72 1.000 0 0 1.000
Nausea during pregnancy (%) 70.8 77.5 0.203 40 55.7 0.192
Entries in boldface were used to show that these variables were significantly related to different or associated with spontaneous miscarriage
SD standard deviation, CRL crown-rump length, BMI maternal body mass index
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Logistic regression equations parameter estimates for
the intercept (b0) and progesterone coefficient (b1) were
(b0, b1) = (2.8439, -0.0971) for the Pilot cohort and
(2.1063, -0.0782) for the Validation cohort. Receiver Op-
erating Characteristic (ROC) analysis was performed on
the Validation cohort data with progesterone level as a
continuous variable.
Validation of serum progesterone for prognosticating risk
of spontaneous miscarriage
AUC (95% CI) for the Pilot and Validation cohort serum
progesterone ROC curves was 0.89 (0.81, 0.97) and 0.83
(0.77, 9.89), respectively. The difference (95% CI) was 0.06
(-0.04, 0.15) and not statistically significant (p = 0.267)
(Fig. 2). In applying the Youden index criterion to the
ROC curve, the progesterone concentration in the Valid-
ation cohort that maximized sensitivity + specificity was
35 nmol/L, which was consistent with the Pilot cohort re-
sult. For the Validation cohort (<35 nmol/L cut-off), test
sensitivity = 65.7%, specificity = 92.0%, Positive Predictive
Value (PPV) = 67.7%, Negative Predictive Value (NPV) =
91.3%, LR + = 8.21 and LR- = 0.37 for spontaneous miscar-
riage by week 16. There were no significant differences be-
tween the Pilot and Validation cohorts among any test
performance parameters (Table 2).
Agreement of actual versus predicted miscarriages by
16 weeks in the validation cohort
Using the <35 nmol/L serum progesterone cut-off,
among the 346 women in the validation cohort, results
were True Positive = 46, True Negative = 254, False Posi-
tive = 24 and False Negative = 22 translating to accuracy
(95% CI) of 300/346 = 0.87 (0.83, 0.90). The null hypoth-
esis of equality of the proportion of miscarriages pre-
dicted by the model (0.197 = 68/346) versus the actual
proportion (0.202 = 70/346) was non-significant by
McNemar’s test (p = 0.768) for the difference (95% CI) of
-0.006 (-0.044, 0.033).
Discussion
There is significant interest in developing clinically use-
ful models for risk prognosis of pregnancy complications
and outcomes, and to stratify pregnant women as low or
high risk. The advantages of serum progesterone as a
marker for spontaneous miscarriage in women with
threatened miscarriage are three-fold: (1) high reliability
for reassuring women at low risk of miscarriage (NPV >
90%), (2) provides clinical guidance for unnecessary pro-
gestogen treatments or bed rest, and (3) may prompt
mobilization of resources supporting an expectant
mother’s psychological wellbeing.
Main findings
Our study was targeted at women presenting with
threatened miscarriage in early pregnancy in order to
validate a previously suggested serum progesterone cut-
off level of <35 nmol/L for predicting risk of spontan-
eous miscarriage in this high-risk population. In the
past, a reliable marker or model for clinical prognosis of
pregnancy outcome in women presenting with threat-
ened miscarriage in early pregnancy has not been avail-
able. In this study, we have successfully validated the
serum progesterone cut-off value of <35 nmol/L (11 ng/
ml)—originally identified in a previous study [12], as a
clinically useful predictor of miscarriage prior to week
Fig. 2 Comparison of ROC curves for serum progesterone from Pilot
and Validation cohorts at < 35 nmol/L cut-off
Table 2 Comparison of sensitivity, specificity, PPV, and NPV
between Pilot and Validation cohorts for progesterone at cut-









































1 Fisher’s exact test, a Prevalence = 0.25; b Prevalence = 0.20
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16 of pregnancy in a temporally different population
from the same centre. Using this cut-off, individual pa-
tients can be quickly stratified as being at low risk or
high risk of spontaneous miscarriage.
Strengths and interpretation
Early pregnancy is maintained via mediation by hor-
mones and endocrine-immune interactions [13]. Proges-
terone is increasingly recognized as a critical hormone
during implantation where it plays an important role in
sustaining decidualization, controlling uterine contractil-
ity and promoting maternal immune tolerance to the
fetal semi-allograft. [14] Thus, high level of serum pro-
gesterone may be protective against early pregnancy loss.
In contrast, low level of serum progesterone could con-
tribute to an increased risk of subsequent spontaneous
miscarriage, especially in women who presents with
threatened miscarriage in the first trimester of preg-
nancy. However, very few studies have reported a spe-
cific cut-off progesterone level with high predictive value
for spontaneous miscarriage [11, 15–17].
The serum progesterone cutoff level of <35 nmol/L
originally proposed by Ku et al [12] provides important
information that can be used to provide individualized
and patient-specific risk assessment for spontaneous
miscarriage. This provides prognostic data available at
entry to care. Our validated proposed cut off level for
serum progesterone allows clinicians to quickly assess
individual patient risk by calculating a probability based
on presence or absence of various factors. This threshold
level for serum progesterone can be applied in a clinical
setting, accurately identifying high-risk patients who
may require more therapeutic intervention or height-
ened surveillance. In addition, this subpopulation of pa-
tients may potentially contribute to further
pharmacological intervention studies whereby its thera-
peutic effectiveness and efficacy can be determined. Al-
though measurements of serum progesterone levels are
not recommended for routine clinical use at this time, it
can be determined that serum progesterone is a highly
specific predictive biomarker for spontaneous miscar-
riage, with a high negative predictive value, allowing us
to reassure anxious patients with a low risk of miscar-
riage. Finally, we are able to demonstrate that our serum
progesterone cut off value of 35 nmol/L was highly re-
producible in a temporally different patient population,
thus supporting the validity of the model.
Limitation
However, our study has a few limitations. This proposed
serum progesterone cut-off value was shown to be ap-
plicable in women who present with threatened miscar-
riage in early pregnancy. It is uncertain if the predictive
values will be applicable in a low-risk population, but
the sensitivity and the specificity should remain con-
stant, as these parameters are independent of disease
prevalence. External validation is required before wide-
spread implementation into clinical practice is possible.
Conclusion
We present a proposed cut off serum progesterone value
of <35 nmol/L as a validated threshold level to predict
spontaneous miscarriage, which demonstrates both ex-
cellent accuracy and acceptable reproducibility. This
threshold level allows clinicians to perform risk stratifi-
cation relating to risk of spontaneous miscarriage, allow-
ing for better prognostication and guiding therapeutic
interventions. This model is both clinically applicable
and easily implemented, as well as provides research op-
portunities for future miscarriage intervention studies.
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